FY2027 EPS Estimates for Omnicell Raised by Zacks Research

Omnicell, Inc. (NASDAQ:OMCL) – Research analysts at Zacks Research raised their FY2027 earnings per share estimates for shares of Omnicell in a research report issued on Thursday, March 5th. Zacks Research analyst Team now expects that the company will earn $1.13 per share for the year, up from their previous estimate of $1.11. Zacks Research has a “Strong Sell” rating on the stock. The consensus estimate for Omnicell’s current full-year earnings is $1.09 per share. Zacks Research also issued estimates for Omnicell’s Q4 2027 earnings at $0.30 EPS and FY2028 earnings at $1.44 EPS.

Omnicell (NASDAQ:OMCL) last issued its earnings results on Thursday, February 5th. The company reported $0.40 EPS for the quarter, missing the consensus estimate of $0.47 by ($0.07). Omnicell had a net margin of 0.17% and a return on equity of 3.00%. The firm had revenue of $313.98 million during the quarter, compared to the consensus estimate of $313.36 million. During the same period in the previous year, the company posted $0.60 EPS. The firm’s revenue for the quarter was up 2.3% on a year-over-year basis. Omnicell has set its Q1 2026 guidance at 0.260-0.360 EPS and its FY 2026 guidance at 1.650-1.850 EPS.

A number of other analysts also recently issued reports on the stock. KeyCorp upgraded shares of Omnicell from a “sector weight” rating to an “overweight” rating and set a $60.00 price objective on the stock in a report on Wednesday, January 7th. Benchmark increased their target price on shares of Omnicell from $50.00 to $60.00 and gave the stock a “buy” rating in a report on Monday, February 2nd. Wells Fargo & Company raised their target price on shares of Omnicell from $43.00 to $52.00 and gave the company an “overweight” rating in a research report on Monday, January 5th. Bank of America upgraded shares of Omnicell from a “neutral” rating to a “buy” rating and set a $70.00 price target on the stock in a research note on Wednesday, February 4th. Finally, Piper Sandler restated an “overweight” rating and set a $49.00 price objective (down from $63.00) on shares of Omnicell in a research note on Friday, February 6th. Five analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, Omnicell presently has a consensus rating of “Hold” and a consensus price target of $54.50.

Omnicell Trading Down 2.2%

NASDAQ:OMCL opened at $41.30 on Friday. The company has a debt-to-equity ratio of 0.14, a current ratio of 1.43 and a quick ratio of 1.22. The business’s 50-day simple moving average is $44.60 and its 200-day simple moving average is $38.26. Omnicell has a fifty-two week low of $22.66 and a fifty-two week high of $55.00. The stock has a market capitalization of $1.88 billion, a PE ratio of 1,032.76, a price-to-earnings-growth ratio of 1.51 and a beta of 0.79.

Insider Buying and Selling at Omnicell

In other Omnicell news, EVP Corey J. Manley sold 6,106 shares of the business’s stock in a transaction dated Thursday, January 8th. The shares were sold at an average price of $49.90, for a total value of $304,689.40. Following the completion of the sale, the executive vice president owned 91,674 shares of the company’s stock, valued at $4,574,532.60. The trade was a 6.24% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Corporate insiders own 2.52% of the company’s stock.

Hedge Funds Weigh In On Omnicell

Hedge funds have recently bought and sold shares of the company. AQR Capital Management LLC grew its position in Omnicell by 42.1% in the first quarter. AQR Capital Management LLC now owns 17,936 shares of the company’s stock valued at $627,000 after acquiring an additional 5,311 shares during the last quarter. Empowered Funds LLC lifted its holdings in shares of Omnicell by 14.3% in the first quarter. Empowered Funds LLC now owns 9,953 shares of the company’s stock worth $348,000 after acquiring an additional 1,243 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in shares of Omnicell by 4.1% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 124,047 shares of the company’s stock valued at $4,337,000 after purchasing an additional 4,866 shares in the last quarter. Jane Street Group LLC grew its holdings in shares of Omnicell by 201.5% during the 1st quarter. Jane Street Group LLC now owns 163,664 shares of the company’s stock valued at $5,722,000 after purchasing an additional 109,382 shares during the last quarter. Finally, Y Intercept Hong Kong Ltd bought a new stake in shares of Omnicell during the 2nd quarter valued at approximately $282,000. 97.70% of the stock is owned by institutional investors.

Omnicell Company Profile

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.